CoronaryAtlas logo
CoronaryAtlas
NLRP3 inflammasome
Pathway / Plaque inflammation

NLRP3 inflammasome

NLRP3protein

NLRP3 inflammasome activation in atherosclerotic plaques and post-MI inflammation generates IL-1β and IL-18, amplifying plaque destabilization and injury response.

Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleInflammasome activation drives atherosclerotic inflammation and atheroinflammatory cytokine release.
Druggability
DruggableNo
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableNo
EnsemblENSG00000162711

Type I vs Type II discrimination

ScoresType-II-associated
R — rupture / Type-I
—
C — confounder / Type-II
67
A — assay feasibility
68
E — evidence strength
86
T1DI (composite)
14
Specificity differential (R−C)-51.7
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
3hypovolemia / dehydrationmag 2
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuremag 2
6hypertensive emergencymag 1
7high-demand / peri-operative stressmag 3
Coverage: 6/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 16 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(15)

Clinical trials(1)